Efficacy of Alkaline Phosphatase in Critically Ill Patients with COVID-19: A Multicentre Investigator-Initiated Double-Blind Randomised Placebo-Controlled Trial.
Anouk PijpeStephan G PapendorpJoost W van der HeijdenBen VerminIris ErtugrulMichael W J RittBjorn StesselIna CallebautAlbertus BeishuizenMarcel VligJoost JimminkHenk J HuijgenPaul P M van ZuijlenEsther MiddelkoopEvelien de JongPublished in: Biomedicines (2024)
Alkaline phosphatase (AP) therapy in COVID-19 ICU patients showed no significant benefits in this trial.
Keyphrases
- double blind
- study protocol
- clinical trial
- placebo controlled
- phase iii
- end stage renal disease
- phase ii
- chronic kidney disease
- coronavirus disease
- ejection fraction
- sars cov
- newly diagnosed
- intensive care unit
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- transcription factor
- cross sectional
- mesenchymal stem cells
- patient reported outcomes
- cell therapy
- bone marrow
- patient reported
- acute respiratory distress syndrome